Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 90

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 90
---
qualified suppliers, of which there are a limited number, for the supply of raw materials, components, devices and manufacturing equipment,
some of which are manufactured or supplied by small companies with limited resources and experience to support commercial pharmaceutical
and biologics production. Additionally, these suppliers may also have upstream suppliers who supply materials, components, devices and
manufacturing equipment, which may indirectly impact our business operations. Thus, the success of our business may be adversely affected
by the underperformance of third parties, exploitation by third parties of our commercial dependence and by unforeseen interruptions to
third parties’ businesses. Although the existence of several alternative suppliers for each function mitigates the risks associated
with this dependence, as does the availability of commercial insurance in respect of the impact of accidental events, the failure of a
third party to properly to carry out their contractual duties or regulatory obligations could be highly disruptive to our business. Supply
chain failures can result in significant clinical or commercial supply interruptions which could materially hamper our ability to conduct
clinical trials or to supply adequate commercial supplies (if any of our product candidates receive marketing authorization), and efforts
to qualify new suppliers can be costly and time consuming. Further, any action taken by a third party that is detrimental to our reputation
could have a negative impact on our ability to register our trademarks and/or market and sell our products, if any.

For some of these raw materials,
components, devices and manufacturing equipment, we rely and may in the future rely on sole source vendors or a limited number of vendors.
The supply of the reagents and other specialty materials and equipment that are necessary to produce our product candidates could be reduced
or interrupted at any time. In such case, identifying and engaging an alternative supplier or manufacturer could result in delay, and
we may not be able to find other acceptable suppliers or manufacturers on acceptable terms, or at all. Switching suppliers or manufacturers
may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If any of our product
candidates receive marketing authorization and we change suppliers or manufacturers for commercial production, applicable regulatory agencies
must approve such changes and may require us to conduct additional studies or trials. If key suppliers or manufacturers are lost, or if
the supply of the materials is diminished or discontinued, we may not be able to develop, manufacture and market our product candidates
in a timely and competitive manner, or at all. An inability to continue to source product from any of these suppliers, which could be
due to a